Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Company...
October 05 2017 - 7:05AM
Presentation at the 2017 SITC Meeting Will
Highlight Preclinical Research on Predicting the Efficacy of Novel
Combination Immunotherapies
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that scientific team
members will present data at upcoming industry meetings.
Preclinical data to be presented at the 2017 Society for
Immunotherapy of Cancer (SITC) annual meeting will examine the
characteristics of the tumor microenvironment to assess the
potential efficacy of novel combination immunotherapies, including
T cell activating therapies formulated with DepoVax-related
technology. Details include:
Name:
“Predicting the efficacy of combination
immunotherapy in animal models using tumor microenvironment immune
cell profiling.”Poster Number:
P297Date:
Friday, November 10,
2017Time:
12:30 to 2 p.m. and 6:30 to 8:00
p.m. ETLocation:
The Gaylord National Hotel & Convention
Center in National Harbor, MD
In addition, clinical study investigators will present a poster
related to Immunovaccine’s Phase 1 data evaluating its
investigational vaccine candidate, DPX-RSV, at the 4th ReSViNET
(Respiratory Syncytial Virus Network) Experts’ Meeting taking place
in Malaga, Spain from November 29 to December 1, 2017.
This poster is entitled “An RSV Vaccine Based on the Small
Hydrophobic Ectodomain Protein Presented with a Novel Lipid-Based
Adjuvant is Highly Immunogenic and Safe in Adults.” Researchers
will discuss the Company’s novel, proprietary target, the SH
ectodomain of the RSV virus, and review the strong safety profile
and the highly immunogenic responses from DPX-RSV, which endured up
to one year from the initial dosing.
Details on the time and location for the ReSViNET poster viewing
will be made available on the Immunovaccine website, under Events,
Webcasts and Presentations.
About DepoVax DepoVax is Immunovaccine’s
proprietary delivery formulation that uses a novel process to
present stimulants to the human immune system, and sustain them
over time .The technology underlying DepoVax formulations suspends
vaccine components in a 100% oil-based diluent that prevents their
release at the site of injection. This process forces immune cells
to take up these components in an active process, delivering them
directly to immune organs such as the lymph nodes. DepoVax
formulations have undergone extensive testing in more than 60
preclinical and seven clinical studies. In clinical trials, these
formulations have consistently demonstrated the ability to generate
robust T and B cell responses, and durable immune responses.
About ImmunovaccineImmunovaccine Inc. is a
clinical stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious
diseases. Immunovaccine develops T cell-activating cancer
immunotherapies and other vaccine candidates based on DepoVax, the
Company’s patented platform that provides controlled and prolonged
exposure of antigens and adjuvant to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through Phase 1 human clinical trials and is currently
conducting a Phase 1b study with Incyte Corporation assessing lead
cancer therapy, DPX-Survivac, as a combination therapy in ovarian
cancer. The Company is also exploring additional applications of
DepoVax, including DPX-RSV, an innovative vaccine candidate for
respiratory syncytial virus (RSV), which has recently completed a
Phase 1 clinical trial. Immunovaccine also has ongoing clinical
projects to assess the potential of DepoVax to address malaria and
the Zika virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking StatementsThis
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E:
info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024